Simultaneous Inhibition of Tumor Growth and Angiogenesis for Resistant Hepatocellular Carcinoma by Co-delivery of Sorafenib and Survivin Small Hairpin RNA

doi:10.1021/mp4006408

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 药物制剂研究中心

	Simultaneous Inhibition of Tumor Growth and Angiogenesis for Resistant Hepatocellular Carcinoma by Co-delivery of Sorafenib and Survivin Small Hairpin RNA
	Shen, Jianan 2; Sun, Huiping 1,2; Meng, Qingshuo 2; Yin, Qi2 ; Zhang, Zhiwen2 ; Yu, Haijun2 ; Li, Yaping2
刊名	MOLECULAR PHARMACEUTICS
	2014-10
卷号	11 期号:10 页码:3342-3351
关键词	sorafenib survivin shRNA co-delivery hepatocellular carcinoma multidrug resistance
ISSN号	1543-8384
DOI	10.1021/mp4006408
文献子类	Article
英文摘要	The development of multidrug resistance (MDR) in human hepatocellular carcinoma (HCC) is one of the major obstacles for successful chemotherapy of HCC. Co-delivery of sorafenib (SF) and survivin shRNA (shSur) was postulated to achieve synergistic effects in reversing MDR, suppressing tumor growth and angiogenesis. For this purpose, in this work, SF and shSur co-loaded pluronic P85-polyethyleneimine/D-alpha-tocopheryl polyethylene glycol 1000 succinate nanocomplexes (SSNs) were first designed and developed for the treatment of drug resistant HCC. The experimental results showed that SSNs could achieve effective cellular internalization and shSur transfection efficiency, induce significant downregulation of the survivin protein, and cause remarkable cell arrest and cell apoptosis. The tube formulation assay demonstrated that SSNs completely disrupted the enclosed capillary networks formed by human microvascular endothelial cells. The in vivo antitumor efficacy showed that SSNs were superior to that of other treatments on drug resistant hepatocellular tumor models. Therefore, it could be an efficient strategy to co-deliver SF and shSur for therapy of drug resistant HCC.
资助项目	National Basic Research Program of China[2012CB932502] ; National Basic Research Program of China[2013CB932704] ; National Basic Research Program of China[2013CB932503] ; National Natural Science Foundation of China[81230029] ; Shanghai program[12nm0501300]
WOS关键词	LUNG-CANCER ; DOWN-REGULATION ; CELLS ; NANOPARTICLES ; INTERFERENCE ; BAY-43-9006 ; APOPTOSIS ; DISEASE ; PROTEIN ; TRENDS
WOS研究方向	Research & Experimental Medicine ; Pharmacology & Pharmacy
语种	英语
出版者	AMER CHEMICAL SOC
WOS记录号	WOS:000342857000013
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/276886]
专题	药物制剂研究中心
通讯作者	Li, Yaping
作者单位	1.Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Peoples R China 2.Chinese Acad Sci, Ctr Pharmaceut, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China;
推荐引用方式 GB/T 7714	Shen, Jianan,Sun, Huiping,Meng, Qingshuo,et al. Simultaneous Inhibition of Tumor Growth and Angiogenesis for Resistant Hepatocellular Carcinoma by Co-delivery of Sorafenib and Survivin Small Hairpin RNA[J]. MOLECULAR PHARMACEUTICS,2014,11(10):3342-3351.
APA	Shen, Jianan.,Sun, Huiping.,Meng, Qingshuo.,Yin, Qi.,Zhang, Zhiwen.,...&Li, Yaping.(2014).Simultaneous Inhibition of Tumor Growth and Angiogenesis for Resistant Hepatocellular Carcinoma by Co-delivery of Sorafenib and Survivin Small Hairpin RNA.MOLECULAR PHARMACEUTICS,11(10),3342-3351.
MLA	Shen, Jianan,et al."Simultaneous Inhibition of Tumor Growth and Angiogenesis for Resistant Hepatocellular Carcinoma by Co-delivery of Sorafenib and Survivin Small Hairpin RNA".MOLECULAR PHARMACEUTICS 11.10(2014):3342-3351.